热门资讯> 正文

Ascendis Pharma将2024年全年SKYTROFA收入展望从3.2亿欧元-3.4亿欧元下调至2.2亿欧元-2.4亿欧元

2024-09-04 05:12

Ascendis制药(ASND) 0
SkyWater Technology(SKYT) 0

As of June 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €259 million, compared to €399 million as of December 31, 2023.
Pending launch timing of YORVIPATH in the U.S., expect to be operating cash flow breakeven on a quarterly basis in 2024 or 2025

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。